The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 2, 2008, Pages 99-105

  Dullaart, R P F ^a   Borggreve, S E ^a   Hillege, H L ^a   Dallinga Thie, G M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cholesteryl ester transfer; Cholesteryl ester transfer protein; Cholesteryl ester transfer protein polymorphism; HDL cholesterol; Triglycerides

Indexed keywords

ADENINE; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CETP GENE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGRESSION ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 41649086518     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701519719     Document Type: Article

References (35)

1. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-84.
2. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
3. Borggreve SE, De Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69.
4. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.
5. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997;17:1053-9.
6. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
7. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-66.
8. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BHR, van Tol A, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-9.
9. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003;44:1080-93.
10. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Bakker SJ, van der Steege G, et al. The effect of CETP -629C>A promoter polymorphism on HDL cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 2005;90:4198-202.
11. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005;111:278-87.
12. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995;96:1664-71.
13. Dachet C, Poirier O, Cambien F, Chapman J, Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels. Role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000;20:507-15.
14. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003;26:1216-23.
15. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-> A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003;12:111-23.
16. Frisdal E, Klerkx AH, Le GW, Tanck MW, Lagarde JP, Jukema JW, et al. Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 2005;14:2607-18.
17. Bernard S, Moulin P, Lagrost L, Picard S, Elchebly M, Ponsin G, et al. Association between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J Lipid Res 1998;39:59-65.
18. Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006;260:151-9.
19. Niemeijer-Kanters SDJM, Dallinga-Thie GM, Ruijter-Heijstek FC, Algra A, Erkelens DW, Banga JD, et al. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis 2001;156:209-16.
20. Channon KM, Clegg RJ, Bhatnagar D, Ishola M, Arrol S, Durrington PN. Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis 1990;80:217-26.
21. Dullaart RP, Riemens SC, Scheek LM, Van TA. Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. Eur J Clin Invest 1999;29:663-71.
22. Sutherland WH, Walker RJ, Lewis-Barned NJ, Pratt H, Tillman HC. Plasma cholesteryl ester transfer in patients with non-insulin dependent diabetes mellitus. Clin Chim Acta 1994;231:29-38.
23. Dullaart RPF, De Vries R, Scheek L, Borggreve SE, van Gent T, Dallinga-Thie GM, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004;64:205-15.
24. Passarelli M, Catanozi S, Nakandakare ER, Rocha JC, Morton RE, Shimabukuro AFM, et al. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B- containing lipoproteins. Diabetologia 1997;40:1085-93.
25. MacLean PS, Vadlamudi S, MacDonald KG, Pories WJ, Barakat HA. Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus. J Clin Endocrinol Metab 2005;90:2250-8.
26. Zhang Z, Yamashita S, Hirano K, Nakagawa-Toyama Y, Matsuyama A, Nishida M, et al. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis 2001;159:67-75.
27. Dullaart RPF, Borggreve SE, De Vries R, Groen AK, van Tol A. Ability of plasma to promote cholesterol efflux out of fibroblasts is associated with the -629C>A cholesteryl ester transfer promoter polymorphism. Eur J Clin Invest 2007;37:A10.
28. Gauthier A, Lau P, Zha X, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005;25:2177-84.
29. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, et al. Association of cholesteryl eater transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323-9.
30. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 2005;178:217-30.
31. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der SG, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91:3382-8.
32. Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BH, van Tol A. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest 2007;37:90-8.
33. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-60.
34. Freeman DJ, Griffin BA, Holmes AP, Lindsay GM, Gaffney D, Packard CJ, et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994;14:336-44.
35. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. J Am Med Assoc 2003;290:2030-40.